Critical Analysis: Autolus Therapeutics (AUTL) versus The Competition

Autolus Therapeutics (NASDAQ:AUTL) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Autolus Therapeutics to related companies based on the strength of its valuation, earnings, dividends, profitability, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Autolus Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-186.37%	-263.25%	-48.04%
Autolus Therapeutics Competitors	-12,323.33%	-195.91%	-30.60%

Insider & Institutional Ownership

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Autolus Therapeutics has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500. Comparatively, Autolus Therapeutics’ rivals have a beta of -1.85, suggesting that their average share price is 285% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Autolus Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1	1	4	2	2.88
Autolus Therapeutics Competitors	9874	15290	45648	1600	2.54

Autolus Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 743.88%. As a group, “Biotechnology” companies have a potential upside of 126.32%. Given Autolus Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Autolus Therapeutics is more favorable than its rivals.

Valuation & Earnings

This table compares Autolus Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Autolus Therapeutics	$75.39 million	-$287.53 million	-1.12
Autolus Therapeutics Competitors	$702.34 million	$9.48 million	-18.83

Autolus Therapeutics’ rivals have higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Autolus Therapeutics beats its rivals on 8 of the 13 factors compared.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing engineered T-cell therapies for cancer. Its treatments are designed to program a patient’s T cells to recognize and attack specific cancer cells, using the company’s proprietary cell-engineering technology. The company’s lead therapy, obecabtagene autoleucel (obe-cel), is marketed as Aucel and is approved in the United States and European Union for certain adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.